Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists): The TOTEM Study

NCT04300881 is registered in ClinicalTrials.gov with Wagner Macula & Retina Center as lead sponsor.

NCT NCT04300881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04300881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists): The TOTEM Study
Lead sponsor
Wagner Macula & Retina Center
Phase
Phase 2
Overall status
Terminated
Start date
October 4, 2019
Completion date
January 5, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subretinal edema, vitreomacular traction